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CR6-interacting factor 1 is a key regulator in Aβ-induced
mitochondrial disruption and pathogenesis of
Alzheimer’s disease
J Byun1,6, SM Son1,6, M-Y Cha1, M Shong2, YJ Hwang3, Y Kim3, H Ryu3,4, M Moon5, K-S Kim5 and I Mook-Jung*,1
Mitochondrial dysfunction, often characterized by massive fission and other morphological abnormalities, is a well-known risk
factor for Alzheimer’s disease (AD). One causative mechanism underlying AD-associated mitochondrial dysfunction is thought to
be amyloid-β (Aβ), yet the pathways between Aβ and mitochondrial dysfunction remain elusive. In this study, we report that CR6-
interacting factor 1 (Crif1), a mitochondrial inner membrane protein, is a key player in Aβ-induced mitochondrial dysfunction.
Specifically, we found that Crif1 levels were downregulated in the pathological regions of Tg6799 mice brains, wherein
overexpressed Aβ undergoes self-aggregation. Downregulation of Crif1 was similarly observed in human AD brains as well as in
SH-SY5Y cells treated with Aβ. In addition, knockdown of Crif1, using RNA interference, induced mitochondrial dysfunction with
phenotypes similar to those observed in Aβ-treated cells. Conversely, Crif1 overexpression prevented Aβ-induced mitochondrial
dysfunction and cell death. Finally, we show that Aβ-induced downregulation of Crif1 is mediated by enhanced reactive oxygen
species (ROS) and ROS-dependent sumoylation of the transcription factor specificity protein 1 (Sp1). These results identify the
ROS-Sp1-Crif1 pathway to be a new mechanism underlying Aβ-induced mitochondrial dysfunction and suggest that ROS-
mediated downregulation of Crif1 is a crucial event in AD pathology. We propose that Crif1 may serve as a novel therapeutic target
in the treatment of AD.
Cell Death and Differentiation (2015) 22, 959–973; doi:10.1038/cdd.2014.184; published online 7 November 2014
Alzheimer’s disease (AD) is the most common and rapidly
growing dementia among the aged population worldwide.
Representative pathologies of AD include the accumulation of
amyloid β (Aβ) plaques, the formation of neurofibrillary
tangles, and massive neuronal loss in the brain.1,2 Although
many studies have focused on the amyloid-β precursor protein
(APP) or Aβ as a therapeutic target, the mechanisms by which
Aβ aggravates AD are not yet fully known. Many possible
scenarios have been suggested based on several lines of
evidence related to mitochondrial dysfunction, oxidative
stress, cerebrovascular damage, and inflammation.3 Among
these hypotheses, abnormal mitochondrial function in AD is
known as a primary causative factor in AD pathogenesis.4,5
In this study, therefore, we focused on a possible mechanism
of mitochondrial dysfunction in the progression of AD.
In mammals, mitochondria are vital organelles participating
in energy production, calcium buffering, signal cascade, and
cell survival.6 Two oxidative metabolic processes, the citric
acid cycle and fatty acid β-oxidation, take place in the
mitochondrial matrix, whereas the oxidative phosphorylation
(OXPHOS in short) system or respiratory chain is embedded
in the mitochondrial inner membrane (MIM). Mitochondria
quality control is regulated by fusion and fission processes,
which are tightly regulated by several proteins, such as
mitofusins (Mfn1 and Mfn2), optic atrophy type 1 (OPA1),
mitochondrial fission 1 protein (Fis1), and dynamin-related
protein 1 (DRP1).7 Mitochondrial dynamics are important for
mitochondrial morphology and function. If the balance
between fusion and fission is disrupted, mitochondrial
morphology is disrupted, and thus, mitochondrial function is
severely impaired.8 Owing to their high-energy metabolic rate,
neurons are highly dependent on mitochondria, and therefore,
neurons are more vulnerable to mitochondrial dysfunction
than other cell types.5 Previous studies revealed that impaired
mitochondrial dynamics are associated with neurodegenera-
tive diseases, including Parkinson’s disease (PD) and
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Huntington’s disease (HD).9 As in other neurodegenerative
diseases, mitochondrial fragmentation has also been
observed in the brains of AD patients.10 Furthermore, elevated
oxidative stress levels were detected in the brains of AD
patients.11 In addition, reduced amounts of mitochondrial
DNA, destructed mitochondrial cristae, and inner/outer
mitochondrial membrane structure are also directly linked to
the increased incidence of AD.12 However, the molecular
mechanisms underlying impairedmitochondrial dynamics and
function in AD are unclear.
CR6-interacting factor 1 (Crif1), also known as GADD45-
associated family protein, was first identified as amolecule that
regulates cell cycle and growth.13,14 Recently, some nuclear
receptors, such as Nur77, STAT3, Elf3, and Nrf2, are also
known to interact with Crif1.15 In addition, Crif1 is important for
the translation of mitochondrial OXPHOS subunits and their
insertion into the MIM.16 In this study, we investigated whether
Crif1 has a role in AD pathogenesis, and found that Crif1 acts
as a key player in Aβ–induced mitochondrial dysfunction. First,
we found that the expression level of Crif1 was reduced in the
brains of ADmouse models as well as in brain tissues from AD
patients. Next, we investigated whether Aβ regulates Crif1
expression levels in vitro, and we found that Crif1 was
decreased significantly in Aβ-treated SH-SY5Y cells compared
with vehicle-treated cells. In addition, this process was
mediated by elevated ROS levels via activation of NADPH
oxidase. To examine themechanism in detail, Aβ-inducedROS
facilitated the reduced binding of the specificity protein 1 (Sp1)
transcription factor on the promoter region of Crif1 by
increasing the sumoylation of Sp1. Reduced Crif1 expression
resulted in the disruption of mitochondrial morphology and its
functions, which leads to massive cell death in AD brains.
Finally, Crif1 overexpression (Crif1 o/e) rescued Aβ-induced
mitochondrial alteration and neuronal cell death. These data
suggest that the regulation of Crif1 could be explored as a
therapeutic target for AD.
Results
Crif1 is decreased in the brains of AD patients and AD
mouse models. To determine whether Crif1 expression is
altered in the brains of AD mice, endogenous Crif1 levels in
the frontal cortex, hippocampus, and cerebellum in 6-month-
old Tg6799 mice were evaluated by western blot analysis
(WB). Crif1 levels were reduced significantly in the frontal
cortex, and the hippocampus of Tg6799 mice compared with
non-transgenic littermate controls, respectively (Figures 1a
and b and Supplementary Figures 1a and b). However, Crif1
levels in the cerebellum of Tg6799 mice were not different
from those in littermate controls (Figures 1a and b),
suggesting that Crif1 reduction occurs only in the pathological
areas of AD. In addition, the expression of Crif1 was
examined by immunohistochemistry using a specific antibody
against Crif1. Both intensity and area fraction of Crif1
fluorescence signal in Tg6799 mouse brains were signifi-
cantly decreased compared with those of littermate controls
(Figures 1c–e). These results were also confirmed in brains
of other AD model mice, such as the APP/PS1 mice
(Supplementary Figure 1c). As PS1 mutations causing
early-onset AD modulate protein expression by disrupting
endoplasmic reticulum homeostasis,17 to determine whether
decreased Crif1 levels in Tg6799 and APP/PS1 mouse
brains were caused by PS1 mutations, we measured Crif1
levels in the brains of 12-month-old Tg2576 mice that carry
only the APP mutation (Supplementary Figure 1c). The levels
of Crif1 were reduced in Tg2576 mice compared with non-
transgenic littermate controls, indicating that Aβ pathology-
bearing mice show a reduction of Crif1 expression regardless
of mutant PS1 expression. To determine whether Crif1 level is
also altered in brains of AD patients, quantitative real-time
PCR (qRT-PCR) and WB analyses in the superior temporal
cortex of human brains, showed a reduction in Crif1 mRNA
and protein levels in AD patients, as much as 35% and 21%,
respectively, compared with control brains (Figures 1f and g).
In addition, immunohistochemical analysis of postmortem
human brain sections, containing the hippocampus, CA3,
and CA1 regions, revealed that the intensity of Crif1 3,
3'-diaminobenzidine (DAB) staining was decreased in AD
patients (Figure 1h, Supplementary Table 1). Overall, these
data indicate that Crif1 expression is reduced in pathological
areas of AD brains.
Aβ1–42 affects Crif1 expression by modulating Crif1
mRNA. The above in vivo data showed reduced Crif1
levels in the pathological regions of AD (Figure 1 and
Supplementary Figure 1), and APP mutation-bearing mouse
models showed decreased Crif1 expression levels
(Supplementary Figure 1b); thus, we determined whether
Aβ, a major risk factor for AD, alters Crif1 expression.
Exogenous Aβ1–42, but not Aβ42-1 (reverse form of Aβ1-42),
decreased endogenous Crif1 levels in SH-SY5Y cells in
time- (Figure 2a) and dose-dependent manners (Figure 2b).
Immunofluorescence experiments, using anti-Crif1 and anti-
HSP60 antibodies, the latter a mitochondria indicator,
showed that Aβ decreased intracellular Crif1 levels
(Figure 2c). To examine whether Aβ-induced Crif1 reduction
is cell specific, Aβ was applied to HT22 cells, the mouse
hippocampal neurons. HT22 cells showed decreased Crif1
levels after Aβ treatment (Supplementary Figure 2a). To
examine the mechanism of downregulation of Crif1 by Aβ in
SH-SY5Y cells, we checked whether Crif1 is degraded by
Figure 1 Crif1 expression was decreased in the brains of mouse models of AD and AD patients. (a and b) WB analysis showed that Crif1 was decreased in the frontal cortex
(not in the cerebellum) of 6-month-old Tg6799 mice (n= 5 per group). Data are presented as mean percentage± S.E.M. **Po0.01, NS indicates no significant difference. (c–e)
Representative micrographs showing immunohistochemistry in the frontal cortex of 6-month-old Tg6799 mice (n= 6 per group). (d and e) Both the intensity (d) and area fraction
(e) of the Crif1 signaling were significantly reduced. The fluorescent signals were captured by fluorescence microscopy and analyzed by Image J software. Data are presented as
mean percentage± S.E.M. **Po0.01. Scale bar represents 20 μm. (f and g) qPCR analysis (f) and WB analysis (g) of brains from AD patients (AD) and controls (normal)
revealed downregulation of Crif1 mRNA and protein expression in AD patients (n= 4 per group), *Po0.05; **Po0.01. (h) Nickel-enhanced diaminobenzidine/peroxidase
reaction showed decreased Crif1 signal in AD patients. Scale bars represent 200 μm (hippocampus) and 20 μm (CA1 and CA3), respectively
The role of CR6-interacting factor 1 in Alzheimer’s disease
J Byun et al
961
Cell Death and Differentiation
The role of CR6-interacting factor 1 in Alzheimer’s disease
J Byun et al
962
Cell Death and Differentiation
degradation pathways such as the proteasome and/or
autophagy-lysosomal pathways. We found that MG132, a
potent proteasome inhibitor,18 and/or 3-methyladenine (3-
MA) and bafilomycin, inhibitors of the autophagy-lysosomal
system,19 failed to rescue Aβ-induced Crif1 reduction
(Figure 2d), suggesting that Aβ-mediated Crif1 regulation
did not occur via protein degradation. Next, we checked for
changes in the transcriptional levels of Crif1 after Aβ
treatment by using qRT-PCR. We found that Aβ reduced
Crif1 mRNA levels without reducing the mRNA levels of other
mitochondrial proteins, such as TOM20 (translocase of outer
mitochondrial membranes 20 kDa) and TIM50 (translocase of
inner mitochondrial membrane 50 kDa), indicating that Aβ
disturbs the transcriptional processing of Crif1 (Figure 2e). In
addition, the reduction of Crif1 mRNA levels lasted for 24 h
after Aβ treatment (Supplementary Figure 2b). These data
indicate that Aβ induced the reduction of Crif1 levels at the
transcriptional level.
Crif1 mRNA is downregulated by Aβ-induced ROS by
facilitating sumoylation of the Sp1 transcription factor.
Previous studies showed that Aβ increased ROS production
via the activation of several pathways, and the increased
ROS has been proposed to have a harmful role in AD
pathogenesis.3,5 To check the effect of ROS on Crif1 levels,
treatment with H2O2 reduced Crif1 levels significantly
(Figure 3a). To determine specifically whether Aβ-induced
ROS generation reduced Crif1 levels, treatment with the ROS
scavenger, N-acetylcysteine (NAC), could rescue Crif1 levels
in Aβ-treated SH-SY5Y cells (Figure 3b), indicating that Crif1
levels are affected by ROS levels, which might be excessively
increased by Aβ.5 ROS are formed as byproducts of
mitochondrial respiration or by the action of oxidases,
including nicotine adenine diphosphate (NADPH) oxidase,
and xanthine oxidase.20 Because Aβ is known to accelerate
ROS generation by activating NADPH oxidase,21 and
Aβ-induced Crif1 reduction is mediated by ROS, we
examined whether NADPH oxidase mediates Aβ-induced
Crfi1 regulation. When treatment of Aβ with apocynin and
diphenyleneiodonium (DPI), well-known NADPH oxidase
inhibitors,22,23 was applied to SH-SY5Y cells, Crif1 levels
showed an increase compared with Aβ-treated cells. These
data indicate that Aβ-induced activation of NADPH oxidase
generates ROS, thereby reducing Crif1 levels. Because
Aβ-induced reduction of Crif1 expression levels is
mediated by transcriptional regulation in Figure 2e, to further
investigate the mechanisms of Crif1 reduction by Aβ, we used
a software program to search for transcription factor-binding
sites with the promoter region sequence of Crif1 (http://www.
genetools.us/genomics/). Through the binding motif analysis,
we identified several candidate transcription factors, including
AML-1A, SRY, and Sp1. Among them, Sp1 is a ubiquitous
transcription factor, and has been previously reported to be
an ROS-sensitive transcription factor for other proteins.24,25
To determine whether Sp1 binds to the Crif1 gene promoter
region, gel electrophoresis mobility shift assay (EMSA) was
performed (Figure 3d). There was a reduction in the moving
distance in a non-denaturing gel because of the binding of
Sp1 to the probe, the Crif1 gene promoter sequence
(Figure 3d, arrowhead). We also found that 5 μM of Aβ
treatment resulted in reduced binding between Sp1 and Crif1
promoter region by detecting a less intense signal on the gel
(Figure 3d, arrowhead). According to previous studies,
sumoylation of Sp1 blocks the cleavage for the negative
regulatory domain of Sp1 and decreases Sp1-dependent
transcription.26 As increased ROS facilitates sumoylation of
many proteins, and high ROS levels have been demonstrated
in AD,5,24,25 we tested the possibility that abnormal over-
production of ROS in AD might cause sumoylation of Sp1,
thereby decreasing Sp1-dependent transcription of Crif1. To
determine whether Aβ increased sumoylation of Sp1, we
performed co-immunoprecipitation (Co-IP) experiments with
Sp1- and SUMO-1-specific antibodies. We found that Aβ
enhanced the interaction between Sp1 and SUMO-1, which
indicates that Aβ-induced Sp1 sumoylation (Figures 3e and f).
To test the effects of Sp1 sumoylation on Crif1 levels, Sp1
wild type and Sp1 K16A, a sumoylation-deficient mutant of
Sp1,27 cDNAs were transfected to SH-SY5Y cells. When Aβ
was applied to cells, Sp1 K16A mutant-transfected cells
showed less decrease in Crif1 levels compared with Sp1
wild-type-transfected cells (Figure 3g). These data indicate
that Aβ-induced reduction of Crif1 is mediated by sumoylation
of Sp1, which negatively affects binding of Sp1 to the Crif1
gene promoter following gene expression.
Crif1 is crucial for maintaining mitochondrial morpho-
logy in SH-SY5Y cells. Previous studies have demonstrated
the disruption of mitochondrial morphology and impaired
mitochondrial function in AD.28 Aβ seems to contribute to
these phenomena, by inducing excessive mitochondrial
fission and failure of the OXPHOS system.29 Disrupted
mitochondrial morphology was consistently observed in the
cortex of Tg6799 mouse brains upon EM analyses (Figure 4a).
Figure 2 Aβ reduced Crif1 levels in SH-SY5Y cells through transcriptional regulation. (a) Crif1 levels were significantly reduced by Aβ (5 μM) in a time-dependent manner.
Data were obtained from at least four replicates for each group (N= 4 experiments). Data are presented as mean± S.E.M. *Po0.05; **Po0.01 versus vehicle (dimethyl
sulfoxide (DMSO))-treated cells. (b) Crif1 levels were significantly decreased by Aβ1-42 (24 h), but not the reversed form of Aβ1-42, in a dose-dependent manner. Data were
obtained from at least four replicates for each group (N= 4 experiments). Data are presented as mean±S.E.M. *Po0.05, **Po0.01. β-Actin is used as a loading control in a and b.
(c) Confocal images showing reduced Crif1 signal in mitochondria of SH-SY5Y cells treated with 2.5 μM Aβ for 24 h. Scale bar represents 10 μm. Quantification of Crif1 signal
was analyzed using the Image J program. Data are represented as mean±S.E.M. from three independent experiments. ***Po0.001. (d) Aβ-induced Crif1 reduction was not
mediated by protein degradation pathway. MG132 (10 μM), 3-MA (2 mM), and bafilomycin (5 nM) were administered 1 h before Aβ treatment, and 24 h after incubation, WB was
performed to measure Crif1 levels. β-Actin serves as a loading control. Representative images are shown. Data are represented as mean± S.E.M. from three independent
experiments. **Po0.01 versus vehicle-treated cells; NS versus Aβ-treated cells. (e) qRT-PCR analysis showed that Aβ decreased Crif1 mRNA levels in SH-SY5Y cells without
affecting mRNA levels of other mitochondrial proteins such as TOM20 and TIM50. Reduced levels of Crif1 after siRNA transfection were detected by qRT-PCR. Data are
represented as the mean± S.E.M. from three independent experiments. *Po0.05, **Po0.01, versus vehicle-treated cells
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Because previous studies show that Crif1 has a critical role in
maintaining mitochondrial function via the integration of
OXPHOS polypeptides into the mitochondrial membrane,16
and Crif1 is mainly located in mitochondria (Supplementary
Figures S3a and b), we investigated whether reduced Crif1
expression causes the disruption of mitochondrial morphol-
ogy. We transfected SH-SY5Y cells with Crif1 siRNA
(Crif1 KD), and the expression of Crif1 was reduced by as
much as about 60% in relation to the control siRNA-
transfected group (Figure 2e and Supplementary Figure
4a). Using a Mito-DsRed-expressing SH-SY5Y cell line, we
analyzed alterations in mitochondrial morphology in control
siRNA (Veh), Aβ-treated control siRNA(Aβ), Crif1 siRNA
(Crif1 KD), and Aβ-treated Crif1 siRNA-transfected cells
(Crif1 KD+Aβ; Figures 4b and c). Consistent with previous
studies, mitochondria were shortened (represented by aspect
ratio) and more circular (represented by form factor) after
treatment with 5 μM of Aβ (Figure 4c). Interestingly, Crif1
knockdown itself (Crif1 KD) could disrupt mitochondrial
morphology resembling that of Aβ-treated control siRNA-
transfected cells (Aβ; Figures 4b and c). In addition,
Aβ-treated Crif1 KD cells (Crif1 KD+Aβ) did not show further
mitochondrial disruption compared with Crif1 KD cells,
indicating that reduced Crif1 levels are sufficient to disrupt
the mitochondrial structure (Figures 4b and c). Furthermore,
massive mitochondrial fission and loss of cristae were
observed in Crif1 KD cells using EM analysis (Figure 4d).
To determine whether Crif1 interacts with mitochondrial
fission/fusion protein, Co-IP with Crif1 and fission/fusion
protein-specific antibodies was performed. We found no
interaction between Crif1 and mitochondrial fission/fusion
proteins (Supplementary Figure 5). These data suggest that
Crif1 is important for maintaining mitochondrial morphology
and that Aβ-induced mitochondrial disruption is mediated by
attenuating Crif1 levels.
Loss of endogenous Crif1 leads to severe defects in
various mitochondrial functions in SH-SY5Y cells. We
determined whether Crif1 regulates mitochondrial function
as well as mitochondrial morphology under Aβ-treated
conditions. When Crif1 siRNA was transfected into SH-
SY5Y cells, the mitochondrial membrane potential (MMP)
was significantly attenuated using JC-1 and TMRM assays
(Figure 4e and Supplementary Figure 6a). In addition, Cirf1
KD cells showed decreased ATP levels by ATP-luciferase
assays (Figure 4f). To check ROS generation, we used the
dichloro-dihydrofluoresceindiacetate and MitoSOX assays,
which showed increased ROS generation in Crif1 KD cells
(Figure 4g, and Supplementary Figure 6b). Overall, these
data indicate that downregulated Crif1 expression induced
mitochondrial dysfunctions as shown in AD condition.
Overexpression of Crif1 rescues Aβ-induced disruption
of mitochondrial morphology. To examine whether Crif1 is
a key molecule for maintaining mitochondrial integrity, either
scrambled or Crif1 cDNA was transfected into SH-SY5Y
cells. When Aβ was administered to the cells, Crif1 over-
expression (o/e) cells showed healthy mitochondria in terms
of length and shape (Figures 5a and b). To further confirm the
role of Crif1 in mitochondrial function, mitochondrial functions
were evaluated after scrambled or Crif1 cDNA transfection
followed by Aβ treatment. Decreased MMPs and ATP
synthesis were not fully, but were significantly, rescued as
much as 50% and 20% in Crif1 o/e cells after evaluation with
JC-1 (Figure 5c) and ATP-luciferase assays (Figure 5d),
respectively. Strikingly, Aβ-induced ROS generation was
completely blocked by Crif1 o/e (Figures 5e and f). These
data show that Aβ decreases Crif1 levels, and enhances
ROS generation, causing impairment in mitochondrial func-
tions. In summary, our data suggest that Crif1 levels are
essential to maintain mitochondrial homeostasis and Aβ-
induced mitochondrial disruption is mediated by decreased
Crif1 expression.
Crif1 levels are important for Aβ-induced cell death in SH-
SY5Y cells. Previous studies have demonstrated that mito-
chondrial dysfunction leads to cell death via intrinsic apoptotic
pathways.30 To determine whether the Aβ-induced decrease in
Crif1 can influence cell viability, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) and Calcein-AM
assays were performed (Figures 6a and b). We found that
Crif1 KD alone, as well as Aβ treatment, caused significant cell
death. Interestingly, overexpression of Crif1 significantly
increased cell viability of Aβ-treated conditions (Figures 6c
and d). To confirm the role of Crif1 on Aβ-induced cell death,
TUNEL (TdT-mediated dUTP Nick-End Labeling) assays were
performed (Figure 6e). Consistent with the results of MTT and
Figure 3 Aβ-induced ROS decreased the transcription of Crif1 gene by facilitating sumoylation of Sp1. (a) Treatment with H2O2-reduced Crif1 levels. 10–750 μM of H2O2
were administered for 6 h into SH-SY5Y cells, and then WB was performed to measure Crif1 levels. GAPDH is used as a loading control. Representative images are shown.
(b) Treatment with a ROS scavenger (NAC; 1 mM) rescued Aβ-induced Crif1 downregulation. β-Actin is used as a loading control. Representative images are shown. Data are
represented as mean±S.E.M. from three independent experiments. **Po0.01 versus vehicle-treated cells; #Po0.05 versus Aβ-treated cells. (c) Inhibition of NADPH oxidase
rescued Aβ-induced Crif1 reduction. Apo (apocynin; 10 μM) or DPI (10 μM) was administered to vehicle- or Aβ-treated cells, and then WB was performed. Representative images
are shown. Data are represented as mean± S.E.M. from three independent experiments (N= 3 experiments). **Po0.01 versus vehicle-treated cells. #Po 0.05, ##Po0.01
versus Aβ-treated cells. (d) EMSA analysis showed that Aβ (5 μM, 24 h treatment) decreased the binding of Sp1 on the promoter region of Crif1. Asterisk (*) represents the
nonspecific band, whereas the black arrowhead (protein-DNA probe complex) represents specific bands. NE indicates ‘nuclear extracts’, Comp indicates ‘competition probe’, and
free probe indicates ‘non-binding probe’. The intensity of the protein-probe complex was analyzed using Image J software. *Po0.05. Representative images are shown (N= 2
experiments). (e, f) Co-immunoprecipitation (Co-IP) analysis showed that sumoylation of Sp1 by SUMO-1 was enhanced after treatment with Aβ. The left panel (e) shows the
increased Sp1-Sumo1 interaction in Aβ-treated cells, and the right panel (f) shows the increased Sp1 sumoylation in Aβ-treated cells using an anti-Sumo1 antibody. The lower
panel (‘Input’) shows a WB of Sp1 and Sumo1, with β-actin as a loading control. Representative images are shown (N= 3 experiments). (g) Sumoylation-deficient mutant form of
Sp1 (Sp1 K16A) shows less reduction in Crif1 levels by Aβ compared with Sp1 wild-type (wt)-transfected cells. β-Actin as a loading control. Representative images are shown.
Data are represented as mean±S.E.M. from five independent experiments (N= 5 experiments). **Po 0.01.versus vehicle-treated Sp1 wt-transfected cells
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Calcein-AM assays, o/e of Crif1 diminished Aβ-induced cell
death. These data indicate that Crif1 levels are crucial for cell
survival in the presence of Aβ.
Discussion
Although many studies have reported that Aβ induces severe
mitochondrial dysfunction, which is believed to have a central
role in AD pathogenesis,12,28–32 how Aβ affects mitochondrial
impairment is not yet fully understood. Previous findings
demonstrated that several MIM structural proteins contribute
to the maintenance of mitochondrial morphology, including
cristae structures.33–35 In a recent report, it was shown that
Crif1 is important for maintaining mitochondrial function, and
alterations in Crif1 levels cause severe mitochondrial
dysfunction.16 However, there were no data regarding the role
of Crif1 in the brain and its relationship to pathological
conditions. Here, we demonstrate the role of Crif1 in the brain
and its regulation, particularly in the pathological condition of
AD. This study provides in vitro and in vivo evidence that
shows that reduced Crif1 levels, mediated by Aβ, cause
mitochondrial defects, resulting in cell death (Figure 7).
Recently, Crif1 was reported to be important for maintaining
mitochondrial function by aiding the insertion of OXPHOS
subunits and stabilizing the MIM integrity.16 In our imaging
data, using super-resolution microscopy, we confirmed that
Crif1 is mainly located in MIM (Supplementary Figure 3); thus,
the reduction in Crif1 levels might affect the stability of the
OXPHOS system in MIM and the energy production required
for cell survival. Furthermore, reduced Crif1 expression in AD
brains would contribute to AD pathology by impairing the
OXPHOS system and mitochondrial functions.
There is increasing evidence that ROS accelerate the
progression of AD pathology during the early period of the
disease.36,37 However, the precise role of ROS in Aβ-induced
neuronal loss has not yet been unraveled. In an effort to
identify signaling molecules underlying the role of Crif1 in AD
pathogenesis, we also found that Aβ-induced downregulation
of Crif1, requires increased levels of ROS. These results were
extended to an additional mechanism that ROS-dependent
sumoylation of the Sp1 transcription factor has a role in Aβ-
induced downregulation of Crif1 expression. Until now, there
was no known transcription factor regulating the expression
levels of Crif1, and we first identified that the ROS-sensitive
transcription factor Sp1, regulates Crif1 levels directly after Aβ
treatment. Previous studies showed that sumoylation of Sp1
attenuates protein stability and decreases the Sp1-dependent
transcription,26 whereas oxidative stress regulates Sp1
activity.38 In addition, Sp1 dysregulation has been reported
in AD brains,39 suggesting that dysregulation of Sp1, by
excessive ROS, might contribute to AD progression. In this
study, we showed that Aβ increased Sp1 sumoylation by using
Co-IP, indicating that Aβ might reduce Crif1 expression
through increased Sp1 sumoylation (Figures 3e and f). Data
obtained using a sumoylation-deficient mutant form of Sp1
confirmed these results (Figure 3g). In addition, co-treatment
of Aβ with NADPH oxidase inhibitors (apocynin and DPI)
rescued Aβ-induced Crif1 reduction in SH-SY5Y cells,
suggesting that Aβ activates NADPH oxidase, resulting in
ROS generation (Figure 3c). Previous reports showed that Aβ
could induce pathological insults, including an increase in
intracellular Ca2+, inflammation, and endoplasmic reticulum
stress, as well as ROS generation.3,5,40 We also examined
whether treatment with a Ca2+ chelator or chemical chaperone
could block Aβ-induced Crif1 reduction. However, these
blockers could not reverse the decrease in Crif1 levels (data
not shown). These data indicate that Aβ induced down-
regulation of Crif1 by elevating ROS level. It is well known that
in vivo ROS levels are enhanced in vulnerable regions that
exhibit AD pathology, such as the cortex and the hippocam-
pus. Xie et al. reported that oxidative stresswasmore dramatic
in neurites near plaques, and rapid cell death by amyloid
plaque-mediated oxidative stress was shown in AD brains.41
In previous studies, no plaques are shown in the cerebellum of
AD brains,42,43 so ROS-induced Crif1 reduction is mainly
demonstrated in the cortex and the hippocampus (Figure 1
and Supplementary Figure 1), but not in the cerebellum
(Figure 1a). Further studies on the Crif1 levels in many other
neurodegenerative diseases, including PD and HD that are
associated with increased ROS levels, should be investigated.
Our data showed that the dysregulation in mitochondrial
dynamics (such as abnormal mitochondrial fission) mediated
by Crif1 KD and/or the treatment with Aβ, induced mitochon-
drial dysfunction, resulting in cell death (Figure 4). However, in
Figures 5 and 6, there is only a slight rescue in MMP and ATP
production by overexpression of Crif1, yet almost we see a
complete reversal of ROS production and apoptosis. There is
an explanation for the results; in previous studies, Aβ is known
Figure 4 Crif1 knockdown (KD) disrupted mitochondrial morphology and impaired mitochondrial function. (a) Massive mitochondrial fission and loss (indicated by arrows)
occurred in the frontal cortex of 6-month-old Tg6799 mice, whereas healthy filamentous mitochondria (indicated by arrowheads) were observed in age-matched littermate
controls. The right panels show figures under higher magnification. Scale bar represents 2 μm (left panels) and 1 μm (right panels). (b and c) Crif1 KD induced increased
mitochondrial fission (b). Mito-DsRed-expressing SH-SY5Y cells were transfected with control siRNA or Crif1 siRNA, and then treated with vehicle or Aβ for 12 h. The images
were obtained by a confocal microscope, and the right panels show figures under higher magnification. (c) Mitochondrial morphology was analyzed using the Image J program
(200 cells for each group). Mitochondria in Crif1 KD cells were shorter (represented by the aspect ratio) and had a more circular shape (represented by the form factor) in
comparison to control siRNA-transfected cells. Data are represented as the mean± S.E.M. from three independent experiments. *Po0.05, **Po0.01, ***Po0.001 versus
vehicle-treated control siRNA-transfected cells. Scale bars represent 10 μm. (d) EM analysis revealed disrupted mitochondrial morphology in Crif1 KD cells similar to Aβ-treated
cells. Arrowheads indicate intact and healthy mitochondria, whereas arrows point to disrupted mitochondria. Scale bar represents 1 μm. (e) The MMP was measured by JC-1
assay. Data presented as mean± S.E.M. of three experiments (N= 3 experiments). *Po0.05, **Po0.01 versus vehicle-treated control siRNA-transfected cells. (f) ATP
generation in Crif1 KD cells was determined by ATP-luciferase assay. Crif1 KD cells show impaired ATP production. Data presented as mean±S.E.M. from three experiments
(N= 3 experiments). *Po0.05, **Po0.01 versus vehicle-treated control siRNA-transfected cells. (g and h) ROS generation in Crif1 KD cells was determined by MitoSOX
staining. (g) Left panel shows phase contrast imaging and right panel shows the fluorescence of MitoSOX dye representing production of mitochondrial superoxide.
(h) Quantification data of g are presented here. Crif1 KD cells show massive ROS generation in mitochondria. Scale bar represents 50 μm. Data are represented as mean±S.E.M.
from three to five independent experiments. *Po0.05, ***Po0.001 versus vehicle-treated control siRNA-transfected cells
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to interact with ATP synthase and cyclophilin D in the
mitochondria,44,45 and then results in decreased ATP produc-
tion and the opening of the mitochondrial permeability
transition pore. Because overexpression of Crif1 cannot block
Aβ binding to its interacting partners, ATP levels and MMP
might be partially, but significantly, rescued in Crif1-
overexpressing cells. However, partially restored ATP, MMP,
and inhibition of ROSmight be enough tomaintain cell survival
as shown in Figures 6c–e.
Previous studies indicated that Aβ can enter the cells,46 and
mediate excitotoxicity by enhancing Ca2+ influx, which
eventually leads to cell death.47 Aβ has been found to induce
mitochondrial Ca2+ overload through a mitochondrial Ca2+
uniporter (MCU). To determine whether Aβ-induced mitochon-
drial Ca2+ overload, induced mitochondria abnormalities and
cell death, Ruthenium red (RuR), a nonspecific inhibitor of the
MCU, and Ru360, a highly specific inhibitor of the MCU,48
were administered to SH-SY5Y cells, and then MTT and
Calcein-AM assays were performed. We found that treatment
with MCU inhibitors (RuR and Ru360) along with Aβ failed to
rescue Aβ-induced mitochondrial dysfunction and cell death
(Supplementary Figures 7a and b). This result indicates that
MCU-dependent Ca2+ influx into mitochondria, have no role in
Aβ-induced mitochondrial dysfunction. Treatment with a ROS
scavenger rescued Aβ-induced mitochondrial dysfunction and
cell death. Our data indicate that Aβ-induced mitochondrial
dysfunction and cell death are mainly mediated by ROS
(Supplementary Figures 7a and b).
There are important MIM proteins that regulate mitochon-
drial morphology, including chchd3, mitofilin, ATP synthase,
and prohibitin.33–35,49,50 Ablation of these proteins is known to
cause the disruption of mitochondrial morphology as well as
severe mitochondrial dysfunction,33,34,51 which was also
observed in Crif1 KD MEF cells.16 Massive neurodegenera-
tion and hyper-phosphorylated tau were observed in
prohibitin-deficient neurons in the forebrain of phb2nko mice,
implying that disruption of mitochondrial morphology by loss of
MIM proteins is closely related to the development of AD
pathology.35 Thus far, there have been no detailed reports
suggesting a close relationship between other MIM proteins
and AD. Therefore, it is highly likely that dysregulation of these
proteins in AD might induce mitochondrial dysfunction, and
their role in AD should be further investigated in future studies.
Collectively, our results identify the ROS-Sp1-Crif1 pathway
to be a new mechanism underlying Aβ-induced mitochondrial
dysfunction and suggest that ROS-mediated downregulation
of Crif1 is a crucial event in AD pathology (Figure 7). To
investigate the relationship between other transcription factors
besides Sp1, and Crif1 levels, inhibitors for several other
transcription factors, including AP-1 and NF-κB, were admi-
nistered together with Aβ into cells, and we found that these
inhibitors did not block the reduction of Crif1 levels by Aβ (data
not shown). Therefore, we hypothesize that the ROS-Sp1-
Crif1 pathway regulates Aβ-induced mitochondrial dysfunc-
tion, which is a crucial event in AD pathology (Figure 7).
Materials and Methods
Animals and human brain samples. We used three different types of AD
model mice: Tg2576 mice (expressing the APP Swedish mutation),52 APP/PS1
mice (expressing Swedish APP and Presenilin1 delta exon 9 mutations),53 and
Tg6799 mice.54 The Tg6799 mice (formerly JAX Stock No. 008730) overexpress
both mutant human APP695 form along with the Swedish (K670N, M671L), Florida
(I716V), and London (V717I) familial AD (FAD) mutations and human PS1 harboring
two FAD mutations, M146L and L286V. All mice were purchased from Jackson
Laboratories (Bar Harbor, ME, USA), and the animals maintained in Seoul National
University’s mouse facility. All experiments were approved by the Institute of
Laboratory Animal Resources of Seoul National University. Human brain tissues for
WB and qRT-PCR were obtained from Boston University, Boston, MA, USA, and
postmortem tissue blocks, containing the hippocampal formation from AD patients
(Braak V-VI) and healthy control donors for immunohistochemistry, were obtained
from the Harvard Brain Tissue Resource Center, Belmont, MA, USA (see
Supplementary Table 1 for additional information of human brain tissues).
Cell culture, transfection, and drug treatment. SH-SY5Y, a human
neuroblastoma cell line, and HT22, an immortalized mouse hippocampal neuronal
cell line, were cultured as previously described.55 Cells were transfected with cDNA
for Crif1 (gifted from Dr. Shong (Chungnam University, Korea)), Sp1 (hMU003598;
provided from Korea Human Gene Bank, Medical Genomics Research Center,
KRIBB, Korea), Sp1 K16A or Mito-DsRed using Lipofectamine and Plus reagents
(Invitrogen, Carlsbad, CA, USA) and Crif1 siRNA (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) using RNAiMax reagents (Invitrogen) for 48 h according to the
manufacturer’s instructions. Cells were grown to 60% confluency and treated with
vehicle (dimethyl sulfoxide) or Aβ1-42 (American Peptide, Sunnyvale, CA, USA),
Aβ42–1 (Bachem, Bubendorf, Switzerland) and various reagents; MG132 (10 μM;
M7449, Sigma-Aldrich, St. Louis, MO, USA), 3-MA (2 mM; M9281, Sigma-Aldrich),
bafilomycin (5 nM; B1793, Sigma-Aldrich), NAC (1 mM; A7250, Sigma-Aldrich),
apocynin (10 μM; A10809, Sigma-Aldrich), DPI (10 μM; D2926, Sigma-Aldrich), and
H2O2 (216763, Sigma-Aldrich).
Western blotting. Harvested cell pellets and mouse brain tissues were
prepared as previously described.56 The antibodies used for WB were: anti-Crif1
(sc-134882), TOM20 (sc-17764), TOM40 (sc-11414), Drp1 (sc-32898), Fis1 (sc-
98900), Mfn1 (sc-50330), and OPA1 (sc-30573) antibodies from Santa Cruz
Biotechnology (1 : 500 for WB); anti-TIM50 (ab23938; 1 : 1000); GAPDH (ab9485;
1 : 3000)antibodies from Abcam; anti-Sp1 antibody (07–645) from Millipore
(Billerica, MA, USA; 1 : 1000); anti-Sumo-1 (4930); HSP60(4870) antibodies from
Cell Signaling Technology (Beverly, MA, USA; 1 : 1000 for WB; 1 : 200 for IP); anti-
β-actin antibody from Sigma-Aldrich (1 : 3000). Immunoreactive bands were
photographed and quantified on an LAS-3000 with Multi Gauge (Fuji Film Inc.,
Tokyo, Japan).
Mitochondrial morphology analysis. Mitochondrial morphology was
investigated using Mito-DsRed-transfected SH-SY5Y cells. Briefly, 5 μM of Aβ
was administered to the cells for 12 h before live-cell imaging or staining process.
Figure 5 Crif1 overexpression restored Aβ-induced mitochondrial dysfunction in SH-SY5Y cells. (a and b) Mock vector or Crif1 cDNA-transfected (Crif1 o/e) Mito-DsRed-
expressed cells were treated with vehicle or 5 μM Aβ for 12 h. In small boxes, enlarged images were converted to 8-bit format to analyze mitochondrial morphology using the
Image J program. Crif1 o/e recovered the increased mitochondrial fission by Aβ in terms of shape (form factor (b)) and length (aspect ratio (b)). Scale bar represents 10 μm. Data
presented as mean±S.E.M. from three experiments (200 cells for each group). *Po0.05, ***Po0.001 versus vehicle-treated mock-transfected cells. #Po0.05, ##Po0.01
versus Aβ-treated mock-transfected cells. (c) The MMP was measured by JC-1 assay. Data presented as mean±S.E.M. of four experiments. ***Po0.001 versus Aβ-treated
mock vector-transfected cells. (d) ATP generation in Crif1 o/e cells was determined by ATP-luciferase assay. Data presented as mean±S.E.M. from three experiments.
***Po0.001 versus Aβ-treated mock vector-transfected cells. (e and f) ROS generation in Crif1 o/e cells was determined by dichloro-dihydrofluoresceindiacetate (DCFDA; e) and
MitoSOX (f) staining. Scale bar represents 10 μm (e) or 20 μm (f). Data are represented as the mean ± S.E.M. of five independent experiments. **Po0.01, ***Po0.001 versus
vehicle-treated mock vector-transfected cells; ###Po0.001 versus Aβ-treated mock vector-transfected cells
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Figure 6 Crif1 levels are important for Aβ-induced cell death in SH-SY5Y cells. (a and b) Crif1 KD induced cell death by MTT assay (a) and Calcein-AM assay (b). Cell
viability assays showed that Crif1 KD enhanced cell death as much as Aβ-treated condition (5 μM, 24 h). *Po0.05, **Po0.01 versus vehicle-treated control siRNA-transfected
cells (c and d) Increased Crif1 expression blocked Aβ-induced cell death. After cDNA transfection for 24 h, 5 μM Aβ was administered for 24 h, and then MTT (c) and Calcein-AM
assay (d) were performed. *Po0.05 versus vehicle-treated mock vector-transfected cells. Data were obtained from at least five replicates per group (N= 5 experiments). (e) To
confirm cell death in Crif1 KD or Crif1 o/e cells, TUNEL assay was performed. Scale bar represents 20 μm. Data are shown as mean± S.E.M. of three independent experiments
(n= 200 each groups, N= 3 experiments). **Po0.01 versus vehicle-treated mock vector-transfected cells; ##Po0.01 versus Aβ-treated mock vector-transfected cells; NS
indicates no significant difference
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Images were taken on a confocal laser scanning microscope (FV10i-w, Olympus,
Tokyo, Japan) and quantified using the Image J program (NIH, Bethesda, MD, USA).
To check for changes in mitochondrial morphology in detail, we used super-
resolution structured illumination microscopy (SIM; Nikon N-SIM). Briefly, a 3D-SIM
image of fixed cells was taken by moving the stage in the z-direction with a optimal
step size (0.150 μm). Images were taken by Eclipse Ti-E research inverted
microscope with Nikon's legendary CFI Apo TIRF × 100 oil objective lens (NA 1.49)
and 512 × 512 pixel resolution with iXon DU-897 EMCCD camera (Andor
Technology, South Windsor, CT, USA).
Mitochondrial function analysis. To measure MMP, TMRM and JC-1
assays were performed. TMRM assay was conducted as previously described. 5 For
the JC-1 assay, we measured green to red ratio after treatment with JC-1 dye
(2 μM). ATP measurements were conducted as previously described.5 ROS levels
were determined using dichloro-dihydrofluoresceindiacetate (Invitrogen) as pre-
viously described.5 Mitochondria-specific ROS were measured using MitoSOX Red
(5 mM for 15 min at 37 °C) following the manufacturer's instructions (Invitrogen). For
all mitochondrial assays, cells were incubated for 24 h after the transfection of
control and Crif1 siRNA or scrambled and Crif1 cDNA. Then, 5 μM Aβ was
administered to cells for 24 h before performing the assays.
Cell viability assay. To measure cell viability, we performed Calcein-AM and
MTT assays as previously described.5 TUNEL assay was performed using the
Deadend Colorimetric TUNEL System (Promega, Madison, WI, USA) according to
the manufacturer’s protocol. To analyze the TUNEL assay results, similar cell
numbers from each group were analyzed (n= 200). Data are represented as the
mean±S.E.M. from three independent experiments. For all cell death assays, cells
were transfected with control and Crif1 siRNA or scrambled and Crif1 cDNA for 24 h
and 5 μM Aβ was administered to cells for 24 h before the assay.
RNA isolation and reverse transcription-PCR. To measure Crif1
mRNA in SH-SY5Y cells, RNA was isolated using the RNeasyPlus Mini Kit (Qiagen,
Valencia, CA, USA) and reverse transcription of the isolated RNA was performed in
vehicle or 5 μM Aβ-treated SH-SY5Y cells. The following sense and antisense
primers were used for human Crif1: 5′-GACAGGCACGC AGCCTACTA-3′ (sense),
5′-ATCATCTGTGGCATCTTGGC-3′ (antisense).
Quantitative real-time PCR. To examine the levels of mRNA of Crif1 or
mitochondrial protein in human brain samples and SH-SY5Y cells, qRT-PCR was
performed as previously described.57 The following sense and antisense primers
were used: 5′-GATGCCACAGATGATTGTGA-3′ (sense), 5′-CCGTTTCTGTTT
TCCTCTCCT-3′ (antisense) for Crif1; 5′-CGACCGCAAAAGACGAAGTGAC-3′
(sense), 5′-GCTTCAGCATCTTTAAGGTCAGG-3′ (antisense) for TOM20; 5′-AGCA
CTATGCCCTGGAGGATGA-3′ (sense), 5′-GAGCCAAGGAAGAGGTTCTGCT-3′
(antisense) for TIM50; 5′-ACAGCCGCATCTTCTTGTGCAGTG-3′(sense), 5′-GGCC
TTGACTGTGCCGTTGAATTT-3′ (antisense) for GAPDH.
Electrophoretic mobility shift assay. To examine the interaction with the
promoter region of Crif1 and Sp1 transcription factor, we performed an EMSA in
vehicle or 5 μM Aβ-treated SH-SY5Y cells for 24 h using the Light Shift
Chemiluminescent EMSA kit (Thermo Scientific, Hudson, NH, USA) following the
manufacturer’s protocol. A double-stranded probe was generated by annealing
two biotin-labeled oligonucleotides against the putative Sp1-binding site
(5′-ACCCGCCCC-3′) within the human Crif1 gene promoter region; forward probe
(5′-biotin-TTTAATCGACCCG CCCCACC-3′) and reverse probe (5′-biotin-GGTG
GGGCGGGTCGATTAAA-3′).
Co-immunoprecipitation. For Co-IP experiments, vehicle or SH-SY5Y cells
treated with Aβ for 24 h were lysed with M-PER mammalian protein extraction
reagent (Thermo Scientific) and processed as previously described.58
Immunostaining. Immunocytochemical staining was performed as previously
described.55 Images were obtained using a confocal laser scanning microscope
(FV10i-w, Olympus). For histological analyses, Tg6799 mice were killed at 6 months
of age (n= 6 per group), brains were sliced and were stained for Crif1 (Santa Cruz
Biotechnology; 1 : 250).40 Immunohistochemistry on human brain tissues was
performed as previously described.59 Briefly, postmortem tissue blocks were cut into
40 μm-serial sections on a freezing sliding microtome (Model 860; American Optical
Company, Buffalo, NY, USA). Sections were stored in cryoprotectant solution (30%
glycerol, 30% ethylene glycol, 0.1% sodiumazide in PB; pH 7.4) at − 20 °C. Tissue
sections were incubated for 48 h with anti-Crif1 (Santa Cruz Biotechnology; 1 : 100),
then the sections were incubated in biotinylated horse anti-mouse IgG antibody
(Vector Laboratories, Burlingame, CA, USA; 1 : 500) for 2 h at room temperature.
Subsequently, the sections were incubated with streptavidin (Invitrogen; 1 : 5000) for
2 h at room temperature. Nickel-enhanced DAB/peroxidase reaction (0.02% DAB
(Sigma-Aldrich), 0.08% nickel-sulfate, 0.006% hydrogen peroxide) was used to
visualize the reaction product.
Aβ1–42 preparation. Aβ1–42 peptide (American peptide, Sunnyvale, CA, USA)
was prepared as previously described.55 Aβ1–42 peptide was dissolved in
1,1,1,3,3,3-hexafluoro-2-propanol (Sigma-Aldrich) to a concentration of 1 mM.
The solution was aliquoted and 1,1,1,3,3,3-hexafluoro-2-propanol was evaporated
by vacuum (SpeedVac Concentrator; Savant Instruments, Hyderabad, India).
The dry peptide was maintained at − 80 1C and dissolved with anhydrous dimethyl
sulfoxide to 1 mM following dilution in Opti-MEM (Invitrogen). Most of Aβ consisted
predominantly of oligomers, and some monomers.56
Statistical analysis. For WB, protein levels were normalized to pan forms or a
housekeeping protein, such as β-actin or GAPDH. All data were expressed as
means± standard error of the mean (S.E.M.). Student’s t-test was used for
two-group comparisons, and analysis of variance, followed by Fisher’s LSD
post-hoc test, was used to compare three or more groups using SigmaStat for
Windows Version 3.10 (Systat Software, Inc., Point Richmond, CA, USA). P values
o0.05 were considered statistically significant.
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Figure 7 Schematic diagram for Aβ-induced mitochondrial dysfunction via ROS-
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expression resulted in disruption of mitochondrial morphology and mitochondrial
functions, which leads to neuronal cell death shown in AD brains
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